158 results about "Metabolism disorder" patented technology

This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and / or atherosclerosis.

The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and / or a body weight disorder, and compositions associated therewith, are provided.

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R is hydrogen, halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; R is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R4 and R5 is hydrogen or hydroxy and the other is hydrogen; or R4 and R5 together are ═O; R6 is hydrogen or alkyl having one, two, three, four or five carbon atoms; or a pharmaceutically acceptable salt of the compound. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

The medicinal composition of effective parts of paeonol, its preparation method and application, is characterized in that the medicinal composition contains 10-40% of paeonol and 10-50% of paeonol total glycosides in terms of weight percentage; wherein, paeonol The total amount of phenol and total paeonol glycosides is not less than 50%. The preparation method is to soak paeonol medicinal material powder or decoction pieces in water, heat and distill, and place the distillate under cooling to precipitate and crystallize paeonol; Solution extraction, the extract and the filtrate are put on a macroporous adsorption resin column, firstly eluted with water, then with alcohol, and the alcohol eluate is collected; the alcohol is recovered under reduced pressure, concentrated and dried to obtain paeonol total glycosides; paeonol and The total glycosides of paeonol are mixed to prepare the composition of effective parts of paeonol. The effective part composition of paeonol cortex of the invention can be used to prepare medicines for preventing and treating fat metabolism diseases and cardiovascular and cerebrovascular diseases.

The present invention relates to a method for preventing and / or treating a fat metabolism disorder and its related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from a fat metabolism disorder and its related conditions, to reduce an abnormal fat deposition at various sites of the body, thereby achieving the purpose of preventing and / or treating a fat metabolism disorder and its related conditions or complications.

A solid oral diagnostic test meal is provided that contains a polysaccharide, wherein the oral diagnostic test meal provides a medically controlled quantity of glycemic carbohydrate after being ingested by a vertebrate subject. In addition, methods and kits are provided for using the diagnostic test meal to monitor postprandial glucose to screen insulin levels and / or diagnose disorders of carbohydrate metabolism, to manage subjects being treated with antidiabetic agents, to self-diagnose diabetes and self-manage diet and antidiabetic drug dosage, and to calculate the glycemic index of a test food.

The invention relates to a circRNA related to subcutaneous fat of pigs and an application thereof, and specifically relates to a circRNA_11897 related to subcutaneous fat of pigs and the application thereof. The invention identifies and analyzes the circRNA of the subcutaneous fat of large white pigs and Laiwu pigs, adopts a systematic bioinformatic method for performing functional analysis on thedifferential expression circRNA and finds the circRNA_11897 and the genes ssc-miR-27a, ssc-miR-27b-3p and SCD related to the circRNA_11897. The experiment proves that the expression quantity of the circRNA_11897 and the genes has a close relation with the subcutaneous fat of pigs. The invention provides a new theoretical basis and a potential target for improving the quality of pork and preventing the happening of metabolic diseases caused by dyslipidemia.

A composition of extracts from plants which can be used for prophylaxis or treatment of metabolism disorder of blood lipid, includes the following ingredients in weight: 3-10 portions of oleanolic acid, 1-5 portions of salvianolic acid, 1-5 portions of danshensu, 1-3 portions of berberine, 1-5 portions of panax notoginseng saponins, 1-5 portions of polysaccharides of atracty-lodes macrocephala koidz, 1-3 portions of aucubin, 1-5 portions of total flavone in cirsium japonicum, 1-5 portions of finger citron polysaccharide, 1-5 portions of panax notoginseng polysaccharides and 1-5 portions of flavones. The use of such composition in manufacturing medicaments used for prophylaxis or treatment of diseases related to metabolism disorder of blood lipid, and the use of such composition in manufacturing health food used for adjuvant prophylaxis or treatment of diseases related to metabolism disorder of blood lipid. Such composition significantly improved the bioavailability, increased the effectiveness, stability, controllability, convenience and safety of medication.